Moreover, as studies indicate anti-FGFR4 therapy may be beneficial toward cardiomyopathy (Grabner et al., 2015), our data suggest these same beneficial outcomes for inflammation, anemia, and skeletal muscle wasting would not apply. The gene discussed is FGFR4; the disease is anemia (phenotype).